Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109192 | 0.88 | SLC1A3 (0.47) | HPGDSHDAC1HDAC3HDAC2ANPEP | |
| SCHEMBL1105703 | 0.85 | — | — | |
| SCHEMBL1109209 | 0.83 | TAAR1 (0.42) | HDAC1HDAC3HDAC2 | |
| SCHEMBL10287228 | 0.83 | PARP1 (0.45) | HPGDSHDAC1HDAC3HDAC2 | |
| SCHEMBL1109400 | 0.82 | CTSB (0.47) | HPGDSANPEP | |
| SCHEMBL1109550 | 0.81 | HPGDS (0.45) | HPGDSANPEP | |
| SCHEMBL1109270 | 0.81 | HDAC3 (0.52) | HDAC1HDAC3HDAC2 | |
| SCHEMBL1109185 | 0.79 | CTSB (0.43) | HPGDS | |
| SCHEMBL1109563 | 0.79 | HPGDS (0.49) | HPGDSHDAC1 | |
| SCHEMBL401441 | 0.78 | HPGDS (0.54) | HPGDSHDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | AAK1 3950/4885HPGDS 253/4885ABCB1 45/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | AAK1 3950/4885HPGDS 253/4885ABCB1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.